Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer

Bevacizumab-based chemotherapy is a recommended first-line treatment for metastatic colorectal cancer (mCRC). Robust biomarkers with clinical practice applicability have not been identified for patients with this treatment. We aimed to evaluate the prognostic yield of serum mid-infrared spectroscopy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Digestive and liver disease 2025-01, Vol.57 (1), p.141-148
Hauptverfasser:	Chautard, Romain, Caulet, Morgane, Bouché, Olivier, Borg, Christophe, Manfredi, Sylvain, Capitain, Olivier, Spano, Jean-Philippe, Raoul, William, Guéguinou, Maxime, Herault, Olivier, Ferru, Aurélie, Pobel, Cédric, Sire, Olivier, Lecomte, Thierry
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Bevacizumab - administration & dosage Bevacizumab - therapeutic use Biomarker Biomarkers, Tumor - blood Cancer Colorectal Neoplasms - blood Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Engineering Sciences Female Humans Life Sciences Male Metastatic colorectal cancer Mid-infrared spectroscopy Middle Aged Optics Photonic Prognosis Progression-Free Survival Prospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!